ArticleNature communications2026
Deep learning coupled with scalable domain-specific structural validation expands RNA virus discovery from metatranscriptomes.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The discovery of RNA viruses from metatranscriptomic data remains challenging due to extreme sequence divergence and length heterogeneity, ranging from massive polyproteins to short assembly artifacts. We present Rider, a two-stage framework that synergizes deep representation learning with scalable domain-specific structural validation. In the first stage, Rider leverages a compact pretrained protein language model to broadly detect highly divergent viral signals. To overcome the inherent input length limitations of language models and accurately capture catalytic core domains, the second stage employs an overlapping sliding-window structure prediction strategy. These structures are then aligned against our curated database of non-redundant RdRp (RNA-dependent RNA polymerase) domains. This domain-centric design detects RdRp domains embedded within long polyproteins and truncated fragments. Across >10,000 metatranscriptomes spanning diverse ecosystems, Rider achieves sensitivity comparable to LucaProt, recalling >99% of previously cataloged RNA viruses. Rider identifies thousands of deeply divergent sequences and clades that elude existing methods. In a human inflammatory bowel disease (IBD) cohort, Rider agrees with other methods in detecting RNA viruses while extending detection to divergent lineages, providing a scalable pipeline for global RNA virome exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.